Literature DB >> 24045609

Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma.

Sravan Kumar Thondam1, Sundus Alusi, Kieran O'Driscoll, Catherine E Gilkes, Daniel J Cuthbertson, Christina Daousi.   

Abstract

Impulse control disorders (ICDs) constitute socially disruptive behaviors such as pathological gambling, impulsive eating, compulsive shopping, and hypersexuality. These conditions are well recognized in patients on dopamine agonist (DA) therapy for Parkinson disease. Dopamine agonists are widely used as first-line agents in the treatment of prolactinomas, but ICDs in this group of patients are relatively rare, perhaps because of lower therapeutic doses used. A review of the literature yielded only a few cases of ICDs in patients on DA treatment for prolactinomas. These symptoms are perhaps underreported because of lack of awareness among patients and health care professionals. Impulse control disorders are recognized psychiatric disorders that have significant psychological and social implications, and patients need to be counselled about this rare possibility when embarking on prolonged DA therapy. We describe a young patient with severe, socially disruptive impulsivity manifesting with pathological gambling who had been on long-term bromocriptine therapy for a macroprolactinoma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24045609     DOI: 10.1097/WNF.0b013e31829fc165

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  8 in total

Review 1.  Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy.

Authors:  Anahid Hamidianjahromi; Nicholas A Tritos
Journal:  Rev Endocr Metab Disord       Date:  2022-09-20       Impact factor: 9.306

Review 2.  Treating prolactinomas with dopamine agonists: always worth the gamble?

Authors:  Sean Noronha; Victoria Stokes; Niki Karavitaki; Ashley Grossman
Journal:  Endocrine       Date:  2015-09-04       Impact factor: 3.633

Review 3.  Gambling disorder during dopamine replacement treatment in Parkinson's disease: a comprehensive review.

Authors:  Domenico Pirritano; Massimiliano Plastino; Domenico Bosco; Luca Gallelli; Antonio Siniscalchi; Giovambattista De Sarro
Journal:  Biomed Res Int       Date:  2014-07-08       Impact factor: 3.411

Review 4.  Impulse Control Behaviors in Parkinson's Disease: Drugs or Disease? Contribution From Imaging Studies.

Authors:  Rosa De Micco; Antonio Russo; Gioacchino Tedeschi; Alessandro Tessitore
Journal:  Front Neurol       Date:  2018-10-25       Impact factor: 4.003

5.  Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study.

Authors:  M Zibetti; S Grottoli; G Beccuti; F Guaraldi; G Natta; V Cambria; N Prencipe; A Cicolin; E Montanaro; L Lopiano; E Ghigo
Journal:  J Endocrinol Invest       Date:  2020-12-12       Impact factor: 4.256

Review 6.  Dopamine Agonists and Impulse Control Disorders: A Complex Association.

Authors:  Marie Grall-Bronnec; Caroline Victorri-Vigneau; Yann Donnio; Juliette Leboucher; Morgane Rousselet; Elsa Thiabaud; Nicolas Zreika; Pascal Derkinderen; Gaëlle Challet-Bouju
Journal:  Drug Saf       Date:  2018-01       Impact factor: 5.606

Review 7.  Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist.

Authors:  Anastasia P Athanasoulia-Kaspar; Kathrin H Popp; Gunter Karl Stalla
Journal:  Endocr Connect       Date:  2018-01-29       Impact factor: 3.335

8.  Identification of driver genes and key pathways of non-functional pituitary adenomas predicts the therapeutic effect of STO-609.

Authors:  Bo Wu; Shanshan Jiang; Xinhui Wang; Sheng Zhong; Yiming Bi; Dazhuang Yi; Ge Liu; Fangfei Hu; Gaojing Dou; Yong Chen; Yi Wu; Jiajun Dong
Journal:  PLoS One       Date:  2020-10-29       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.